This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Geisinger Health Plan, offering medical coverage in Pennsylvania, recently announced that Brainsway’s depression treatment threpay will be now be covered under their insurance policies. This coverage applies to over half a million beneficiaries. From The Health Plan website: